| Edição |
Seção |
Título |
Arquivo |
| Nº 5 (2012) |
Articles |
THE DIAGNOSIS AND TREATMENT OF PAPILLOMAVIRUS INFECTION-ASSOCIATED DISEASES: NEW DIRECTIONS AND CONTROVERSIAL ISSUES |
|
| Nº 7 (2013) |
Articles |
PAPILLOMAVIRUS INFECTION CAUSED BY HUMAN PAPILLOMAVIRUS TYPES 52 AND 58 AND ITS ROLE IN THE DEVELOPMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIAS |
|
| Nº 1 (2014) |
Articles |
Relationship between HPV-associated genital and anal neoplasias, their diagnosis and treatment |
|
| Nº 9 (2015) |
Articles |
HPV-associated diseases of the cervix uteri: Novelty in diagnosis |
|
| Nº 12 (2015) |
Articles |
PREVALENCE OF ANOGENITAL HPV TYPES IN PATIENTS WITH HPV-ASSOCIATED DISEASES OF THE CERVIX UTERI |
|
| Nº 1 (2016) |
Articles |
MOLECULAR MARKERS OF CERVICOVAGINAL FLUID: NOVELTY IN THE DIAGNOSIS AND PREDICTION OF HUMAN PAPILLOMAVIRUS-ASSOCIATED DISEASES |
|
| Nº 2 (2016) |
Articles |
Mir-29 expression in the cervical epithelium in cervical intraepithelial neoplasias |
|
| Nº 5 (2016) |
Articles |
HPV-ASSOCIATED CERVICAL DISEASES IN WOMEN WITH AUTOIMMUNE DISEASES: VACCINATION |
|
| Nº 2 (2016) |
Articles |
Prediction of the risk and progression of cervical intraepithelial neoplasias associated with papillomavirus infection |
|
| Nº 4 (2017) |
Articles |
Proteomic composition of cervicovaginal fluid in cervical diseases associated with HPV infection |
|
| Nº 3 (2017) |
Articles |
Lipidomics: New perspectives on search for markers of neoplasia |
|
| Nº 5 (2017) |
Articles |
Predicting the risk of cervical intraepithelial neoplasia associated with HPV infection malignisation using the combination of proteomics and transcriptomics |
|
| Nº 3 (2017) |
Articles |
Differential diagnosis of cervical intraepithelial neoplasia of varying severity via quantitative assessment of anti-oncogenic microRNA expression |
|
| Nº 9 (2017) |
Articles |
“Lesser abnormalities” of cervical lesions associated with human papilloma virus: Diagnostics, monitoring, prognosis |
|
| Nº 9 (2017) |
Articles |
Diagnosis of squamous intraepithelial lesions and cervical cancer based on the quantitative assessment of microRNA expression |
|
| Nº 4 (2018) |
Articles |
Lipid markers of cervical epithelium neoplastic transformation in HPV-associated diseases |
|
| Nº 4 (2018) |
Articles |
Prevalence of HPV types in patients with cervical intraepithelial neoplasia of different severity |
|
| Nº 4 (2018) |
Articles |
Minor cervical lesions associated with human papillomavirus: diagnosis, monitoring, prognosis |
|
| Nº 12 (2018) |
Articles |
High-risk human papillomavirus persistence and other molecular genetic predictors for cervical intraepithelial neoplasias |
|
| Nº 11 (2019) |
Articles |
Lipidomic markers and prospects for their use in human papillomavirus-associated cervical diseases |
|
| Nº 8 (2019) |
Articles |
PROSPECTS FOR THE PREVENTION OF HPV-ASSOCIATED CANCER |
|
| Nº 2 (2020) |
Articles |
Human papillomavirus-associated anogenital diseases: clinical and molecular genetic features |
|
| Nº 7 (2020) |
Articles |
Characteristics of dynamic changes in proteomic composition of cervicovaginal fluid in cervical diseases associated with HPV infection |
|
| Nº 3S (2021): Supplement |
Articles |
SOVREMENNYE PRINTsIPY KONSUL'TIROVANIYa V KONTRATsEPTsII. GORMONAL'NAYa KONTRATsEPTsIYa |
|
| Nº 10 (2021) |
Articles |
Application of molecular genetic methods for the diagnosis and prediction of severe dysplasia and cervical cancer |
|
| Nº 5 (2022) |
Articles |
Proteomic analysis of cervicovaginal fluid of patients with HPV-associated cervical lesions treated with activated glycyrrhizic acid |
|
| Nº 9 (2020) |
Articles |
Human papillomavirus genotyping results of human papillomavirus vaccinated women of reproductive age |
|
| Nº 4 (2024) |
Guidelines for the Practitioner |
Combined hormonal contraceptive containing estetrol and drospirenone: pharmacokinetics and opportunities forclinical use |
|
